Clinical Trials Directory

Trials / Terminated

TerminatedNCT01794247

Intrathecal Magnesium for Same-day-surgery

Intrathecal Magnesium Associated to Lidocaine Decreases the Incidence of the Transitory Neurologic Syndrome Following Same-day-surgery

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Hospital General de Ciudad Real · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

5% hyperbaric lidocaine has lost its usefulness for same-day-surgery (SDS) anaesthesia because it has been blamed responsible for the so-called transitory neurological syndrome (TNS). This entity appears particularly in patients operated on lithotomy and knee arthroscopy position and obese patients. It is a benign, moderately painful (grade 3-4 out of 10) and self-limited in time, but disturbing enough to be avoided in same-day-surgery cases. Other local anesthetics are not competitive with general anesthesia in time to be discharged home from the SDS unit. The magnesium ion is well-known for its protective properties on cells with electrical activity. The objective is to confirm that the magnesium ion added as adjuvant to intrathecal (IT) lidocaine may antagonize TNS incidence. If this hypothesis could be confirmed, the practical and theoretical consequences would be far-reaching. The method to achieve our objective would be a double-blinded randomized clinical trial considering two groups of intrathecal lidocaine: with and without added IT magnesium.

Conditions

Interventions

TypeNameDescription
DRUGMagnesium sulfate
DRUGFentanyl
DRUGLidocaine

Timeline

Start date
2013-04-01
Primary completion
2013-12-01
Completion
2014-03-01
First posted
2013-02-18
Last updated
2014-03-10

Locations

2 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT01794247. Inclusion in this directory is not an endorsement.